Toll-like receptors, endogenous ligands, and systemic autoimmune disease

Immunological Reviews

Volumn 204, Issue , 2005, Pages 27-42

  Rifkin, Ian R ^a   Leadbetter, Elizabeth A ^b   Busconi, Liliana ^a   Viglianti, Gregory ^a   Marshak Rothstein, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; AUTOANTIGEN; COMPLEMENT COMPONENT C1Q; DEOXYRIBONUCLEASE I; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; LIGAND; LIPOPEPTIDE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PEPTIDOGLYCAN; PROTEIN TYROSINE KINASE; RHEUMATOID FACTOR; SERUM AMYLOID P; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DAMAGE; CELL DEATH; CHROMATIN; CHRONIC DISEASE; DENDRITIC CELL; DISEASE MODEL; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MAMMAL; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; DNA; HUMANS; IMMUNITY, NATURAL; LIGANDS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS;

EID: 16244376480     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00239.x     Document Type: Review

References (142)

1. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002;111:927-930.
2. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257-263.
3. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-351.
4. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekowitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.
5. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 2004;14:277-287.
6. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
7. Overzet K, et al. Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. Arthritis Rheum 2000;43:1327-1336.
8. Gilligan HM, et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996;184:2231-2241.
9. Sauter B, Albert ML, Francisco L, Larsson M, Someran S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-433.
10. Boes M, Schmidt T, Linkemann K, Beaudette B, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000;97:1184-1189.
11. Aprahamian T, et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004;199:1-12.
12. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
13. Casiano CA, Martin SJ, Green DR, Tan EM. Cleavage of a subset of nuclear antigens associated with different functions during CD95 (Fas/Apo-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-778.
14. Degen WGJ, van Aarssen Y, Pruijn GJM, Utz PJ, van Venrooij WJ. The fate of the U1 small nuclear RNP complex during anti-fas induced apoptosis: specific cleavage of the U1 snRNA molecule. Cell Death Differ 2000;7:70-80.
15. Casciola-Rosen LA, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: Implication for initiation of autoimmunity. J Exp Med 1999;190:815-825.
16. Cheung WL, et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 2003;113:507-517.
17. Huck S, Deveaud E, Namane A, Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J 1999;13:1415-1422.
18. Lunec J, Herbert K, Blount S, Griffiths HR, Emery P. 8- Hydroxydeoxyguanosine: a marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994;348:131-138.
19. Utz PJ, Gensler TJ, Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res 2000;2:101-114.
20. Navratil JS, Sabatine JM, Ahearn JM. Apoptosis and immune responses to self. Rheum Dis Clin North Am 2004;30:193-212.
21. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.
22. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:323-324.
23. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
24. Bell JK, Mullen GED, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003;24:528-533.
25. Hornung V, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-4537.
26. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.
27. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001;108:1097-1104.
28. Eriksson U, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003;9:1484-1490.
29. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 2004;113:990-997.
30. Anders HJ, et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004;18:534-536.
31. Li J, Stein TD, Johnson JA. Genetic dissection of systemic autoimmune disease in Nrf2 deficient mice. Physiol Genomics 2004;18:261-272.
32. Garg DK, Ali R. Reactive oxygen species modified polyguanylic acid: Immunogenicity and implications for systemic autoimmunity. J Autoimmunity 1998;11:371-378.
33. Lee J, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;1000:6646-6651.
34. Goodnow CG, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988;334:676-682.
35. Nemazee DA, Buerki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989;337:562-566.
36. Rathmell JC, Goodnow CG. Effects of the lpr mutation on elimination and inactivation of self-reactive B cells. J Immunol 1994;153:2831-2842.
37. Kench JA, Russell DM, Nemazee D. Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J Exp Med 1998;188:909-917.
38. Shlomchik MJ, Zharhary D, Camper S, Saunders T, Weigert M. A rheumatoid factor transgenic mouse model of autoantibody regulation. Int Immunol 1993;5:1329-1341.
39. Jacobson BA, Sharon J, Shan H, Shlomchik M, Weigert MG, Marshak-Rothstein A. An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-lpr/lpr mouse exhibits limited intraclonal affinity maturation. J Immunol 1994;152:4489-4499.
40. Hannum LG, Ni D, Haberman AM, Weigert MG, Shlomchik MJ. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J Exp Med 1996;184:1269-1278.
41. Wang H, Shlomchik MJ. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J Exp Med 1999;190:639-649.
42. Uwatoko S, et al. C1q-binding immunoglobulin G in MRL/1 mice consists of immune complexes containing antibodies to DNA. Clin Immunol Immunopathol 1995;75:140-146.
43. Rifkin IR, et al. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol 2000;165:1626-1633.
44. Pancer LB, Milazzo MF, Morris VL, Singhal SK, Bell DA. Immunogenicity and characterization of supernatant DNA 1released by murine spleen cells. J Immunol 1981;127:98-104.
45. Bell DA, Morrison B, VandenBygaart P. Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 1990;85:1487-1496.
46. Emlen W, Holers VM, Arend WP, Kotzin B. Regulation of nuclear antigen expression on the cell surface of human monocytes. J Immunol 1992;148:3042-3048.
47. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B Cells by CpG dsDNA. Immunity 2003;19:837-847.
48. Leadbetter EA, Rifkin IR, Hohlbaum AH, Beaudette B, Shlomchik MJ, Marshak-Rothstein A. Immune complexes activate autoreactive B cells by co-engagement of sIgM and Toll-like receptors. Nature 2002;419:603-607.
49. Wang H, Shlomchik M. High affinity rheumatoid factor transgenic B cells are eliminated in normal mice. J Immunol 1997;159:1125-1134.
50. Li M, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-7135.
51. Vabulas RM, et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-31339.
52. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991;147:1759-1764.
53. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
54. Bauer S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-9242.
55. Adachi O, et al. Targeted disruption of the Myd88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 1998;9:143-150.
56. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115-122.
57. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Cur Biol 2000;10:1139-1142.
58. Hacker H, et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998;17:6230-6240.
59. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and liposaccharides activate Toll-like receptors at distinct compartments. Eur J Immunol 2002;32:1958-1968.
60. Matsumoto M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154-3162.
61. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacxine, chloroquine and structurally related compunds. J Immunol 1998;160:1122-1131.
62. Drose S, Altendorf K. Bafilomycins and Concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol 1997;200:1-8.
63. Benaroch P, et al. How MHC class II molecules reach the endocytic pathway. EMBO J 1995;14:37-49.
64. Marshak-Rothstein A, et al. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res 2004;10:247-251.
65. Yi A-K, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 1998;160:4755-4761.
66. Krieg AM, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631-12636.
67. Lenert P, Stunz L, Yi A-K, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-κB activation. Antisense Nucleic Acid Drug Dev 2001;4:247-256.
68. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003;22:621-631.
69. Suzuki K, et al. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci USA 1999;96:2285-2290.
70. Zhu F-G, Reich CF, Pisetsky DS. Effect of cytofectins on the immune response of murine macrophages to mammalian DNA. Immunol 2003;109:255-262.
71. Goeckeritz BE, et al. Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotides motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. Int Immunol 1999;11:1693-1700.
72. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev 1995;5:309-314.
73. Brooks WH. Systemic lupus erythematosus and related autoimmune diseases are antigen-driven, epigenetic diseases. Med Hypotheses 2002;59:736-741.
74. Rui L, Vinusa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003;4:594-600.
75. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002;297:2066-2070.
76. Fields M, Erikson J. The regulation of lupus-associated autoantiodies: immunoglobulin transgenic models. Cur Opin Immunol 2003;15:709-717
77. Sano H, Morimoto C. DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J Immunol 1982;128:1341-1345.
78. Li JZ, Steinman CR. Plasma DNA in systemic lupus erythematosus. Characterization of cloned base sequnces. Arthritis Rheum 1989;32:726-733.
79. Krug A, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001;31:3026-3037.
80. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196-202.
81. Batteux F, Palmer P, Daeron M, Weill B, Lebon P. FCγRII (CD32)-dependent induction of interferon-α by serum from patients with lupus erythematosus. Eur Cytokine Netw 1999;10:509-514.
82. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003;171:3296-3302.
83. Hardin JA. Directing autoimmumty to nucleoprotein particles: the impact of dendritic cells and interferon alpha in lupus. J Exp Med 2003;197:681-685.
84. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002;195:1653-1659.
85. Tan PS, et al. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003;170:2549-2556.
86. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004;199:1631-1640.
87. Sutterwala FS, Noel GJ, Clynes R, Mosser DM. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 1997;185:1977-1985.
88. Mackay F, et al. Mice transgenic for BAFF develop lymphocyte disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-1710.
89. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
90. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
91. Heil F, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-1529.
92. Lund JM, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:6835-6836.
93. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J Biol Chem 2004;279:12542-12550.
94. Koski GK, Kariko K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004;172:3989-3993.
95. Roman MJ, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406.
96. Hahn BH. Systemic Lupus Erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-2380.
97. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
98. Navab M, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007.
99. Silverman GJ, et al. Neo-self antigens and the expansion of B-1 cells: lessons from atherosclerosis-prone mice. Curr Top Microbiol Immunol 2000;252:189-200.
100. Binder CJ, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-1226.
101. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993;268:11811-11816.
102. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 1995;92:9580-9584.
103. Sawamura T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77.
104. Walton KA, et al. Receptors involved in the oxidized 1-palmitoyl-2- arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003;278:29661-29666.
105. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/ MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278:1561-1568.
106. Lee JY, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004;279:16971-16979.
107. Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY, Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993;28:599-605.
108. Michelsen KS, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004;101:10679- 10684.
109. Wright SD, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000;191:1437-1442.
110. Bjorkbacka H, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-421.
111. Kirii H, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:656-660.
112. Elhage R, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003;59:234-240.
113. Kiechl S, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-192.
114. Ameziane N et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003;23:e61-64.
115. Beg AA. Endogenous ligands of Toll-like receptors: Implications for regulating inflammatory and immune responses. Trends Immunol 2002;23:509-512.
116. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003;23:15-44.
117. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-478.
118. Bausinger H, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol 2002;32:3708-3713.
119. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514-519.
120. Johnson GB, Brunn GJ, Platt JL. An endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004;172:20-24.
121. Oyama J, et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004;109:784-789.
122. Shishido T, et al. Toll-like receptor 2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-2910.
123. Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-59.
124. Bickerstaff MCM, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-697.
125. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001;293:306-311.
126. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosis in DNase1-deficient mice. Nat Genet 2000;25:177-180.
127. Shaw PX, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-1740.
128. Kim SJ, Gershov D, Ma X, Brot N, Elkon KB. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation, J Exp Med 2002;196:655-665.
129. Sambrano GR, Steinberg D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc Natl Acad Sci USA 1995;92:1396-1400.
130. Hanayama R, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004;304:1147-1150.
131. Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001;293:618-619.
132. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of Toll-like receptors. Curr Top Microbiol Immunol 2002;270:169-184.
133. Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 2003;100:15824-15829.
134. Park JS, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7377.
135. Okamura Y, et al. The Extra Domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276:10229-10233.
136. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 2001;167:2887-2894.
137. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168:5989-5992.
138. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168:5233-5239.
139. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004;279:17079-17084.
140. Termeer C, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002;195:99-111.
141. Lien E, Ingalis RR. Toll-like receptors. Crit Care Med 2002;30:S1-S11.
142. Zhang D, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522-1526.